Finance & markets · 18/11/20261 min read
mAbxience and OncoPrecision Announce Manufacturing and Investment Agreement for OncoPrecision's ADC Candidate ONC001
Summary
MADRID, Nov. 18, 2026 — mAbxience, a wholly owned company of Fresenius SE & Co. KGaA, and OncoPrecision, a biotechnology company pioneering first-in-class precision therapies for hard-to-treat cancers through the integration of patient-derived biology and AI, headquartered...